Psilocybin Study for Treatment - Resistant Depression
Official Title
A Phase III, multicentre, randomised, double-blind,
controlled study to investigate the efficacy, safety,
and tolerability of two initial administrations of
COMP360 in participants with treatment-resistant
depression
controlled study to investigate the efficacy, safety,
and tolerability of two initial administrations of
COMP360 in participants with treatment-resistant
depression
Purpose
The study investigates a new approach for treatment-resistant depression using an investigational medicine related to psilocybin alongside psychological support.
Could this study be right for you?
You may be able to join the study if you:
— Are 18 years of age or older
— Have been diagnosed with major depression and have not responded to 2+ antidepressants
Other criteria will need to be met to confirm your eligibility for this study, which will last up to 62 weeks.